ALFA Finder| Revenue growth | 23.4% Y-o-Y for pharmacy operations. |
|---|---|
| Margins | Consolidated EBITDA 5.8%; mature stores (12m+) at 13.1% store-level EBITDA. |
| Demand visibility | Stable; driven by network densification and omnichannel convenience. |
| Management confidence | High; intent to stabilize and grow margins through private label mix. |
Growth
Pharmacy revenue grew 23.4% Y-o-Y. Private label sales reached 22% of total revenue. Diagnostics segment grew to INR 347.8 million.
Outlook
Guided 800 net new stores for FY27. Targeting 9-10% annualized SSSG and maintaining 5.7-5.8% EBITDA margins while scaling private labels.
Risks
Higher store closures (77 in Q4) primarily due to underperformance in older stores and relocation. Private label scaling depends on customer conversion.
Earnings Call filed with NSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹625.80
- Market cap
- ₹7,519 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 35.6×Sector 54.5×
- Promoter holding
- 40.19%+0.00% QoQ
- FII holding
- 12.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus subsidiary Optival Health received a two-day drug licence suspension for its Kothagudem store. Expected financial impact is Rs 0.44 lacs, and compliance measures are underway.
- Value
- ₹0.00 Cr
Medplus Health Services Adverse Business Impact
MedPlus stores in Karnataka face four-day drug licence suspensions. Expected financial impact is about Rs 4.06 lacs.
- Value
- ₹0.04 Cr
- Execution
- Four days
Medplus Health Services Capital Structure Change
MedPlus approved a buyback of 17.33 lakh shares at ₹750 each, up to ₹130 crore. The buyback equals about 1% of paid-up capital via open market.
- Value
- ₹130.0 Cr
Medplus Health Services Adverse Business Impact
MedPlus Health Services' subsidiary Optival Health Solutions had its drug licence suspended for five days for a Suryapet store. Expected financial impact is about Rs 1.32 lakh.
- Value
- ₹0.01 Cr
- Execution
- 05 days
Medplus Health Services Board Meeting Date
MedPlus Health Services scheduled a board meeting for 6 November 2026 to consider a share buy-back. The trading window for designated persons closes from 30 October 2026.
Medplus Health Services Capital Structure Change
ICICI Prudential Mutual Fund disclosed under Regulation 29(2) that it bought 24,35,693 Medplus shares, lifting its stake to 9.21%. The acquisition was made in the open market, not off-market.
- Promoter stake change
- +1.97%